The Target of Hair Loss Treatment Is Changing: The Rise of RNA Therapy [Kim Jin-oh's Hair Loss Escape]

[Financial News] Until now, male pattern hair loss has been treated with drugs whose effectiveness and safety have been proven. However, even the best medicine cannot deliver satisfying results for everyone. As the need for a new treatment emerged, RNA therapy appeared.
RNA therapy is being praised for opening a new chapter by selectively intervening in the process that causes hair loss and reducing systemic side effects. In South Korea, OliX is conducting clinical trials of an RNA therapy for male pattern hair loss, while Bioneer Corporation is actively developing RNA-based treatments, including a scalp-applied product built on a similar mechanism.
So what exactly is RNA therapy, and what role will it play in future hair loss treatment? At first glance, the name may suggest a treatment that changes genes, but the RNA therapy now being developed for hair loss does not do that.
Inside cells, DNA contains the instructions for making proteins, and those instructions are copied into RNA, which acts as a messenger. RNA interference therapy finds and breaks down specific messenger RNA, thereby reducing the production of androgen receptors, the proteins that contribute to hair loss. This approach allows doctors to selectively control a target without altering genetic information.
If targeted control can regulate the androgen response in hair follicles without significantly lowering DHT throughout the body, it could become a new option for people who have been concerned about the side effects of existing treatments. If it works sufficiently in the scalp while being detected only at very low levels in the blood, it may offer a safety profile different from that of existing oral drugs. However, the fact that it is injected into the scalp alone does not prove that it has no systemic side effects. Data on blood levels after repeated dosing and long-term safety are needed.
It is also worth studying how it could be used together with existing hair loss drugs. Finasteride and dutasteride reduce DHT production, while RNA therapy lowers androgen receptors. Because they inhibit the same pathway at different stages, combining them could produce a stronger effect. On the other hand, if RNA therapy proves effective enough on its own, it may also be possible to reduce the dose or treatment burden of existing drugs. These possibilities must be tested in clinical trials after the efficacy and safety of monotherapy have been confirmed.
The duration of effect is also very important in RNA therapy. If treatment can be given every few weeks or months instead of requiring daily pills or topical applications, convenience would improve significantly.
The realistic role of RNA therapeutics is likely not to replace existing drugs, but to fill the gaps in treatment. They could offer a local treatment option for people who have difficulty taking oral drugs, add a different mechanism for those who have not responded sufficiently to current therapies, and provide longer dosing intervals for those who struggle with daily medication.
RNA therapy is still under development. Clinical Phase 2 studies and later research must confirm the size of the effect, how long it lasts, the safety of repeated dosing, and the cost. But it would be wrong to dismiss its potential simply because it is still early in development. Bioneer Corporation has already turned a topical RNA technology into a real product, and OliX is moving into the stage of verifying efficacy after repeated administration of an injectable RNA medicine in humans.
It is still too early to know whether RNA therapeutics will become a complete solution for hair loss. Even so, they could provide another option for people who cannot use existing drugs and may improve both the effectiveness and convenience of current treatment. What needs to be confirmed in the future is not how new the technology sounds, but how much hair actually changes and how long that change lasts.

/Kim Jin-oh, CEO of New Hair Hair Transplant Clinic
[email protected] Kim Hyun-sun Reporter